Table 1 ACS Group: Clinical profile and aPL prevalence
ACS+: HIV+ | ACS+: HIV- | p value | |
|---|---|---|---|
Demographic Profile: | |||
Black African n(%) | 30(100) | 30(100) | 1.0 |
Mean Age (years) | 43 ± 7 | 54 ± 13 | < 0.001 |
Men (%) | 20(67) | 18(60) | N/S |
Coronary risk factors n(%): | |||
Smoking | 22(73) | 10(33) | 0.004 |
Diabetes Mellitus | 1(3) | 7(23) | 0.05 |
Hypertension | 7(23) | 23(77) | < 0.001 |
Total cholesterol (mmol/l) | 3.6 ± 1.0 | 4.6 ± 1.4 | 0.003 |
LDL cholesterol (mmol/l) | 2.2 ± 0.9 | 3.0 ± 1.2 | 0.003 |
HDL cholesterol (mmol/l) | 0.8 ± 0.3 | 1.1 ± 0.4 | < 0.001 |
Triglycerides (mmol/l) | 1.4 ± 0.8 | 1.1+/-0.4 | N/S |
BMI (kg/m2) | 25 ± 5 | 28 ± 5 | 0.008 |
Other coronary risk factors | 2(7) | 16(53) | < 0.001 |
Baseline aPL frequencies(%): | |||
Blood samples n(%) | 30(100) | 29(97)* | N/S |
Anticardiolipin (IgG) | 14(47) | 3(10) | 0.003 |
Anticardiolipin (IgM) | 3(10) | 1(3) | N/S |
Anticardiolipin (IgA) | 0(0) | 3(10) | N/S |
Beta-2 Glycoprotein (IgG) | 11(37) | 6(21) | N/S |
Beta-2 Glycoprotein (IgM) | 3(10) | 0(0) | N/S |
Beta-2 Glycoprotein (IgA) | 7(23) | 12(41) | N/S |
Anti-Prothrombin (IgG) | 26(87) | 6(21) | < 0.001 |
Anti-Prothrombin (IgM) | 2(7) | 0(0) | N/S |
Anti-Prothrombin (IgA) | 2(7) | 1(3) | N/S |
Antiphospholipid syndrome (%): | 8/18(44) | 6/25(24) | N/S |